The treatment, designated as a breakthrough therapy by the FDA, supports patients with symptomatic tenosynovial giant cell tumors that didn’t respond to surgery.
Surgery is the primary treatment option, but some patients are not eligible for surgery or have tumors reappear after surgery.
Turalio, made by Basking Ridge, N.J.-based Daiichi Sankyo, comes with a warning about the risk of serious liver toxicity.
More articles on pharmacy:
Pfizer to merge off-patent business with Mylan
Senate panel advances drug-pricing legislation
Average chief pharmacy officer salary by state
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.